Literature DB >> 7772042

Inhibition of myeloperoxidase by benzoic acid hydrazides.

A J Kettle1, C A Gedye, M B Hampton, C C Winterbourn.   

Abstract

Myeloperoxidase is the most abundant protein in neutrophils and catalyses the conversion of H2O2 and chloride into HOCl. To help clarify the role of this enzyme in bacterial killing and inflammation, a specific and potent inhibitor needs to be identified. We have studied a series of benzoic acid hydrazides and found that in general they inhibit the peroxidation activity of myeloperoxidase with an IC50 value of less than 10 microM. The IC50 values of derivatives with substituents containing oxygen or nitrogen were related to their Hammett substituent constants. This indicates that myeloperoxidase oxidizes the hydrazide group of these compounds, and the degree to which they inhibit the enzyme is dependent on the ease of their oxidation. Unsubstituted benzoic acid hydrazide and its 4-chloro derivative were poor inhibitors of peroxidation. Thus it is likely that hydrogen-bonding of the enzyme to substituents containing oxygen or nitrogen increases the binding affinity of the hydrazides and enhances their oxidation by myeloperoxidase. 4-Aminobenzoic acid hydrazide (ABAH) was the most potent inhibitor of peroxidation. It irreversibly inhibited HOCl production by the purified enzyme, having an IC50 value of 0.3 microM. With neutrophils stimulated with opsonized zymosan or phorbol myristate acetate, ABAH inhibited HOCl production by up to 90% and the IC50 values were 16 microM and 2.2 microM respectively. In the presence of superoxide dismutase, these values decreased to 6.4 microM and 0.6 microM respectively. ABAH had no effect on superoxide radical (O2-.) production and degranulation by neutrophils, nor did it inhibit catalase or glutathione peroxidase. Thus ABAH is an effective and selective inhibitor that should be useful for determining the contribution of myeloperoxidase to oxidant-mediated reactions of neutrophils.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7772042      PMCID: PMC1136962          DOI: 10.1042/bj3080559

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  24 in total

1.  The measurement of lysozyme activity and the ultra-violet inactivation of lysozyme.

Authors:  D SHUGAR
Journal:  Biochim Biophys Acta       Date:  1952-03

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Assays for the chlorination activity of myeloperoxidase.

Authors:  A J Kettle; C C Winterbourn
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

4.  Reassessment of Ellman's reagent.

Authors:  P W Riddles; R L Blakeley; B Zerner
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Superoxide modulates the activity of myeloperoxidase and optimizes the production of hypochlorous acid.

Authors:  A J Kettle; C C Winterbourn
Journal:  Biochem J       Date:  1988-06-01       Impact factor: 3.857

6.  Isoniazid-mediated irreversible inhibition of the myeloperoxidase antimicrobial system of the human neutrophil and the effect of thyronines.

Authors:  J M van Zyl; K Basson; R A Uebel; B J van der Walt
Journal:  Biochem Pharmacol       Date:  1989-07-15       Impact factor: 5.858

7.  Inhibition of the myeloperoxidase-H2O2-Cl- system of neutrophils by indomethacin and other non-steroidal anti-inflammatory drugs.

Authors:  E Shacter; R L Lopez; S Pati
Journal:  Biochem Pharmacol       Date:  1991 Mar 15-Apr 1       Impact factor: 5.858

8.  Salicylhydroxamic acid inhibits myeloperoxidase activity.

Authors:  M Ikeda-Saito; D A Shelley; L Lu; K S Booth; W S Caughey; S Kimura
Journal:  J Biol Chem       Date:  1991-02-25       Impact factor: 5.157

9.  Superoxide is an antagonist of antiinflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase.

Authors:  A J Kettle; C A Gedye; C C Winterbourn
Journal:  Biochem Pharmacol       Date:  1993-05-25       Impact factor: 5.858

10.  Inactivation of catalase by phenylhydrazine. Formation of a stable aryl-iron heme complex.

Authors:  P R Ortiz de Montellano; D E Kerr
Journal:  J Biol Chem       Date:  1983-09-10       Impact factor: 5.157

View more
  45 in total

1.  Spectrophotometric determination of leukocytes in blood.

Authors:  Huriye Kuzu-Karsilayan; Eda Eryilmaz; Gaye Yillar; Günnur Deniz; Gülderen Yanikkaya-Demirel
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

2.  Aminobenzoic acid hydrazide, a myeloperoxidase inhibitor, alters the adhesive properties of neutrophils isolated from acute myocardial infarction patients.

Authors:  Lili Han; Xiaoli Shen; Leng Pan; Saimei Lin; Xiaoqing Liu; Yulian Deng; Xiaodong Pu
Journal:  Heart Vessels       Date:  2011-08-12       Impact factor: 2.037

3.  DNA-based fluorescent probes of NOS2 activity in live brains.

Authors:  Aneesh T Veetil; Junyi Zou; Katharine W Henderson; Maulik S Jani; Shabana M Shaik; Sangram S Sisodia; Melina E Hale; Yamuna Krishnan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-17       Impact factor: 11.205

4.  Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity.

Authors:  Kathleen D Metzler; Tobias A Fuchs; William M Nauseef; Dominique Reumaux; Joachim Roesler; Ilka Schulze; Volker Wahn; Venizelos Papayannopoulos; Arturo Zychlinsky
Journal:  Blood       Date:  2010-10-25       Impact factor: 22.113

5.  2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation.

Authors:  Anna-Karin Tidén; Tove Sjögren; Mats Svensson; Alexandra Bernlind; Revathy Senthilmohan; Francoise Auchère; Henrietta Norman; Per-Olof Markgren; Susanne Gustavsson; Staffan Schmidt; Stefan Lundquist; Louisa V Forbes; Nicholas J Magon; Louise N Paton; Guy N L Jameson; Håkan Eriksson; Anthony J Kettle
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

6.  Inhibition of Myeloperoxidase.

Authors:  Jala Soubhye; Paul G Furtmüller; Francois Dufrasne; Christian Obinger
Journal:  Handb Exp Pharmacol       Date:  2021

7.  Demyelinating diseases: myeloperoxidase as an imaging biomarker and therapeutic target.

Authors:  Reza Forghani; Gregory R Wojtkiewicz; Yinian Zhang; Daniel Seeburg; Benjamin R M Bautz; Benjamin Pulli; Andrew R Milewski; Wendy L Atkinson; Yoshiko Iwamoto; Elizabeth R Zhang; Martin Etzrodt; Elisenda Rodriguez; Clinton S Robbins; Filip K Swirski; Ralph Weissleder; John W Chen
Journal:  Radiology       Date:  2012-03-21       Impact factor: 11.105

8.  Myeloperoxidase Molecular MRI Reveals Synergistic Combination Therapy in Murine Experimental Autoimmune Neuroinflammation.

Authors:  Anning Li; Yue Wu; Benjamin Pulli; Gregory R Wojtkiewicz; Yoshiko Iwamoto; Cuihua Wang; Jing-Hui Li; Muhammad Ali; Xiaoyuan Feng; Zhenwei Yao; John W Chen
Journal:  Radiology       Date:  2019-09-03       Impact factor: 11.105

9.  Mechanism of horseradish peroxidase inactivation by benzhydrazide: a critical evaluation of arylhydrazides as peroxidase inhibitors.

Authors:  Susan M Aitken; Marc Ouellet; M David Percival; Ann M English
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

10.  Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates.

Authors:  Louisa V Forbes; Tove Sjögren; Françoise Auchère; David W Jenkins; Bob Thong; David Laughton; Paul Hemsley; Garry Pairaudeau; Rufus Turner; Håkan Eriksson; John F Unitt; Anthony J Kettle
Journal:  J Biol Chem       Date:  2013-11-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.